Clinical Trials Logo

Clinical Trial Summary

Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03354429
Study type Interventional
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Status Recruiting
Phase Phase 3
Start date January 22, 2018
Completion date December 16, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03463551 - Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic Phase 2
Completed NCT02164357 - Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset N/A
Recruiting NCT01207336 - Combined tDCS+PNS After Acute Stroke Phase 2/Phase 3
Recruiting NCT03328403 - Endovascular Therapy in Acute Ischaemic Stroke Due to Large Vessel Occlusion N/A
Recruiting NCT03639922 - Imatinib in Acute Ischaemic Stroke Phase 3
Recruiting NCT03541668 - Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) Phase 3
Not yet recruiting NCT03578822 - Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial Phase 3
Completed NCT01994720 - [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] Phase 3
Terminated NCT01745692 - Pragmatic Ischaemic Stroke Thrombectomy Evaluation N/A